Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9086970 | 0.83 | MEN1 (0.44) | MEN1KMT2AALDH1A1TDP1NLRP3 | |
| SCHEMBL2226469 | 0.83 | MEN1 (0.44) | MEN1KMT2AALDH1A1TDP1TSHR | |
| SCHEMBL14795068 | 0.83 | MEN1 (0.44) | MEN1KMT2AALDH1A1TDP1NLRP3 | |
| SCHEMBL9188074 | 0.79 | MEN1 (0.46) | MEN1KMT2AMCL1TSHRDPP4 | |
| SCHEMBL11869141 | 0.76 | MEN1 (0.39) | MEN1KMT2AMCL1 | |
| SCHEMBL10011134 | 0.74 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL11561721 | 0.73 | MEN1 (0.44) | MEN1KMT2AALDH1A1TDP1NLRP3 | |
| SCHEMBL28035557 | 0.71 | MEN1 (0.42) | MEN1KMT2AALDH1A1TDP1NLRP3 | |
| SCHEMBL10935407 | 0.71 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL10011135 | 0.71 | MEN1 (0.46) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483247-B1 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| US-7229993-B2 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-06-12 | — | — | US | disclosed |
| EP-1483247-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2004-12-08 | — | — | EP | disclosed |
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | EURO-CELTIQUE S.A. | 2003-12-25 | — | — | US | disclosed |
| WO-2003076414-A2 | ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF | EURO-CELTIQUE S.A. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236273-A1 | Aryl substituted pyrimidines and the use thereof | CACNA1S, CACNA1C, NCS1 | MEN1 4871/4885KMT2A 3789/4885ALDH1A1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.